XNCR Xencor Inc
Price Chart
Executive Summary
Xencor reported final Phase 1 data for XmAb942, an anti-TL1A antibody for IBD, showing a terminal half-life of 74.1 days, favorable safety, and low immunogenicity (0% neutralizing antibodies at target dose). The company also presented preclinical data for XmAb412, a TL1A x IL23p19 bispecific, with predicted human half-life of 60-70 days. Enrollment in the Phase 2b XENITH-UC study remains on track with a blinded interim analysis expected around year-end 2026 and primary endpoint results in 2H27.
Actionable Insight
XmAb942 Phase 1 data supports best-in-class profile with 74-day half-life enabling Q12W SC dosing and low immunogenicity. The XENITH-UC Phase 2b blinded interim around YE26 is the next major catalyst. XmAb412 FIH start in 3Q26 adds pipeline optionality. Monitor for partnership interest given precedent valuations shown ($1.5B-$10B+).
Key Facts
- XmAb942 Phase 1 estimated terminal half-life of 74.1 days from pooled single-dose cohorts
- 0% neutralizing antibodies (NAb+) at XENITH-UC target dose regimen; 25% ADA+ at target dose
- 86% of patients predicted to achieve >99% TL1A inhibition at induction (Week 12) per QSP model
- 90% of patients predicted to achieve >90% TL1A inhibition at maintenance (Week 52) with Q12W SC dosing
- No serious or severe TEAEs; TEAE rates similar between XmAb942 (75%) and placebo (69%)
- XmAb412 predicted human half-life of 60-70 days; NHP half-life >20 days
- XmAb412 FIH study expected to begin 3Q26
- XENITH-UC Phase 2b enrolling ~220 patients; blinded interim analysis ~YE26, primary endpoint 2H27
- Cash position ~$611M as of Dec 31, 2025
Financial Impact
No financial data reported; clinical-stage biotech with ~$611M cash position
Risk Factors
- Phase 2b XENITH-UC results may not replicate Phase 1 PK/PD predictions
- Competitive landscape includes multiple first-gen anti-TL1A programs (afimkibart, tulisokibart, duvakitug) in Phase 3
- ADA incidence of 57% across all doses could impact long-term efficacy if neutralizing antibodies emerge
- No revenue-generating products; dependent on pipeline success and partnerships
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000036 |
| Document: xncr-20260504xexx992.htm | 0001326732-26-000036 |
| Document: xncr-20260504.htm | 0001326732-26-000036 |
| Document: 0001326732-26-000036-index-headers.html | 0001326732-26-000036 |
| Document: 0001326732-26-000036-index.html | 0001326732-26-000036 |
| Document: 0001326732-26-000036.txt | 0001326732-26-000036 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 6, 2026
5w ago
|
8-K
| $12.31 $11.42 | ▲ +7.23% | ▲ +10.37% | $12.33 (−0.16%) |
|
May 5, 2026
5w ago
|
8-K
| $12.85 $11.21 | ▼ −12.76% | ▼ −17.72% | $12.33 (−4.05%) |
|
Apr 27, 2026
6w ago
|
8-K
| $12.15 $11.63 | ▼ −4.28% | ▼ −9.75% | $12.33 (+1.48%) |
|
Mar 5, 2026
14w ago
|
Insider Cluster
| $11.16 $12.81 | ▲ +14.78% | ▲ +18.57% | $12.33 (+10.48%) |
|
Mar 4, 2026
14w ago
|
8-K
| $11.16 $12.81 | ▼ −14.78% | ▼ −18.57% | $12.33 (−10.48%) |
|
Feb 25, 2026
15w ago
|
8-K
| $11.98 $12.40 | ▲ +3.51% | ▲ +8.74% | $12.33 (+2.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access